Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study analyzed the economic burden of alopecia areata in Saudi Arabia, finding significant costs driven by productivity loss and drug expenses, with severe cases incurring higher expenses, emphasizing the need for better treatment protocols and access to therapies.

This study found that targeting the AR/miR-128-3p/IGF-1 pathway with ASLNC168501 shows potential for treating androgenetic alopecia by restoring hair follicle stem cell function and promoting hair regeneration.

In this study, a taurine-based ionic liquid was developed to effectively penetrate the skin barrier and deliver antioxidants to hair follicles, reducing oxidative stress and promoting hair regrowth in an androgenic alopecia animal model.

In this study, baricitinib treatment for severe alopecia areata showed similar safety and led to hair regrowth improvements independent of atopic background, with 40.8% of patients with atopy achieving a significant response compared to 30.2% without atopy when using a 4 mg dose.

In this study, PA-011, a traditional Chinese medicine extract, was shown to improve hair growth in alopecia areata model mice by reducing skin inflammation and altering skin microbiota, indicating its potential therapeutic role for this condition.

In this clinical study involving individuals with localized alopecia areata, TrA injections were found to significantly outperform MTX, leading to better hair regrowth and higher patient satisfaction, though both treatments had similar mild side effects.

This study reports that an Explainable AI-based hair health prediction system using a novel hybrid model outperformed traditional machine learning methods, achieving high accuracy in predicting key factors and providing personalized recommendations.

Contact immunotherapy can change immune responses in alopecia areata, suggesting new treatment targets.

This study reports a novel geometric medicine solution, N‑K GM SERIES, claiming to eliminate aflatoxin, offer a universal cancer cure, and provide numerous health benefits, including increased life expectancy, with deployment focused on the "Aflatoxin Belt" regions like Sudan.

This study developed a low-viscosity triamcinolone acetonide serum, used with a derma stamp microneedling device, to improve targeted treatment of alopecia areata, reporting favorable drug solubility, spreadability, and permeation to hair follicles, while maintaining skin safety.

This study found that multidisciplinary group medical visits for patients with alopecia areata improved patient satisfaction, knowledge, and access to care at Lahey Hospital and Medical Center.

This review discusses the use of antiandrogens like flutamide and its derivatives in prostate cancer treatment and highlights the need for next-generation antiandrogens for improved efficacy; it reports no new clinical results.

This review highlights advancements in the understanding and treatment of alopecia areata, noting that the approval of oral Janus kinase inhibitors like baricitinib and ritlecitinib marks a significant development in managing severe cases of this autoimmune condition.

In this study, the researchers explored how the loss of structural integrity in hair follicles due to reduced α-SMA expression in the vertex area may contribute to androgenetic alopecia.

This article discusses alopecia areata incognito, highlighting its diffuse hair loss pattern and favorable response to steroid treatment, but it reports no new clinical data.

This study found that intralesional Candida antigen was as effective as intralesional steroids for treating alopecia areata after 5 months, with significantly lower injection pain reported in the Candida group.

This study found that two novel nonsteroidal derivatives inhibited specific enzymes in vitro and in vivo, leading to dihydrotestosterone accumulation in androgen-dependent glands, suggesting potential therapeutic use for mood improvement in the elderly.

Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.

This review discusses the clinical challenges in treating alopecia areata with off-label therapies, highlighting the need to consider new research on JAK inhibitors, but reports no new clinical results.

In this study, researchers found that the AIRE G961C variant is a significant risk factor for severe alopecia areata and early-onset cases, particularly in patients with alopecia universalis.

This study suggests that the residues Val-889 and Arg-752 in the androgen receptor steroid binding domain are crucial for the intermolecular interaction necessary for receptor dimerization and function.

This review discusses laser and energy-assisted drug delivery as a treatment for alopecia and concludes that although all studies show positive effects, some reports indicate no superiority over existing monotherapies.

This review discusses treatment options for alopecia areata and suggests tailored treatment plans, noting the challenges posed by spontaneous remission and limited high-quality clinical trials.

This study found that combining the PAXMAN scalp cooling system with HairRepro MEDI α lotion led to a 50% success rate in reducing chemotherapy-induced alopecia and achieved complete hair regrowth by 3 months in Japanese breast cancer patients, suggesting enhanced efficacy over scalp cooling alone.

This study reported that IL-15 promotes human hair growth and protects hair follicle immune privilege, potentially stabilizing alopecia areata treatment outcomes when selectively stimulating IL-15Rα signaling.

This study found that immunotherapy with DNCB or DPCP showed better therapeutic effects than intralesional triamcinolone acetonide for patients with bald areas greater than 50 cm², including alopecia totalis and universalis.

This study found that the rs3185480 polymorphism in the APCDD1 gene was associated with an elevated risk of developing androgenic alopecia and reduced protein levels, potentially due to altered codon usage affecting translation efficiency.

This review discusses the critical parameters for MALDI IMS sample preparation in skin analysis and highlights its applications in wound healing, neoplasia, and infection research, but reports no new clinical results.